Theriva Biologics (TOVX) Income from Continuing Operations (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Income from Continuing Operations of 2044000.0 for Q1 2026, up 52.73% year-over-year from 1338318.59 in Q1 2025, and down 2.4% quarter-over-quarter from 1996000.0 in Q4 2025.
Theriva Biologics (TOVX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Income from Continuing Operations for 17 consecutive years, with 2044000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 52.73% year-over-year to 2044000.0; the TTM figure through Mar 2026 stood at 21459000.0 (up 13.52% YoY), while the FY2025 annual figure was 18754000.0, up 7.46% from the prior year.
- Income from Continuing Operations fell to 2044000.0 in Q1 2026 per TOVX's latest filing, from 1996000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 1996000.0 in Q4 2025 and bottomed at 13058000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 5412176.47 across 5 years, with a median of 4478000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 133.91% — and 2025, when it jumped 55.12%.
- Theriva Biologics' Income from Continuing Operations stood at 7872000.0 in 2022, then grew by 16.25% to 6593000.0 in 2023, then jumped by 32.55% to 4447000.0 in 2024, then surged by 55.12% to 1996000.0 in 2025, then decreased by 2.4% to 2044000.0 in 2026.
- Business Quant data shows TOVX's Income from Continuing Operations at 2044000.0 in Q1 2026, 1996000.0 in Q4 2025, and 4361000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | -3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.22 Mn |
| Mar 31, 2026 | -2.04 Mn |
| Dec 31, 2025 | -2.00 Mn |
| Sep 30, 2025 | -4.36 Mn |
| Jun 30, 2025 | -13.06 Mn |
| Mar 31, 2025 | -4.32 Mn |
| Dec 31, 2024 | -4.45 Mn |
| Sep 30, 2024 | -7.73 Mn |
| Jun 30, 2024 | -8.32 Mn |
| Mar 31, 2024 | -5.17 Mn |
| Dec 31, 2023 | -6.59 Mn |
| Sep 30, 2023 | -3.30 Mn |
| Jun 30, 2023 | -5.08 Mn |
| Mar 31, 2023 | -4.48 Mn |
| Dec 31, 2022 | -7.87 Mn |
| Sep 30, 2022 | -4.49 Mn |
| Jun 30, 2022 | -4.48 Mn |
| Mar 31, 2022 | -4.27 Mn |
| Dec 31, 2021 | -5.34 Mn |
| Sep 30, 2021 | -3.41 Mn |